Want to see AU:CGS full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.05Last Year’s EPS
0.06Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and forward visibility: record new trial starts, a 105% jump in sales contracts, solid YoY revenue/backlog growth, expanding channel partnerships, and a healthy cash balance. Short‑term margin pressure and a $0.5M doubtful debt provision were acknowledged, largely driven by deliberate investments in delivery capacity, timing of contract recognition and one‑off adjustments. Management expects margins to recover in H2 as contracted revenue converts and maintains a clear strategy of diversification and technology investment to sustain medium‑term growth.Company Guidance
Significant Growth in Trial Portfolio
Managing 133 clinical trials as at 31 Dec, up 34% year‑on‑year, with a record 42 new trial starts in the December half (most active half-year ever).
Record Sales Contracts in December Half
Clinical trial sales contracts totaled $41.7M in the December half, an increase of 105% versus the prior corresponding period and the second-best half-year sales result historically.
Revenue Above Guidance and Year‑on‑Year Growth
First half revenue was $26.9M, ahead of guidance (~$25–26M) and up 12% year‑on‑year (despite being ~8% below the most recent June half due to timing effects).
Diversification into New Indications
Almost 6x growth in the value of sales contracts in mood, sleep and other neurological disorder programs in the December half; 45% of contract value derived from mood/sleep/other neuro in the half, showing strong traction in depression and psychiatry.
Channel Partner Momentum
Channel partners drove 70% of sales opportunities and 62% of executed sales contracts in the December quarter, demonstrating scalable go‑to‑market expansion without margin dilution when co‑selling.
Healthy Backlog and Forward Contracting
Clinical trials backlog revenue of $92.3M (up 9% YoY); $21.7M of revenue contracted for the June half (up 24% YoY) and $27M of revenue contracted for FY27 (up 13% YoY), providing good forward visibility.
Profitability and Margin Leverage
EBITDA of $6.5M (24.3% margin), profit before tax $5.3M (~20% margin) and profit after tax $4.5M (16.7% margin), illustrating operational leverage despite growth investments.
Investing in Technology and AI
Invested ~$2.2M in technology modernization during the half; approximately USD 500–600k spent on AI‑powered monitoring and AI‑powered rater training projects now in scale‑up toward commercial readiness.
Strengthened Delivery Capacity
Clinical trial delivery headcount increased by 17% (to ~90 FTEs in clinical trials) and clinician consultant network grew 25% YoY, supporting expansion into new indications and more complex service offerings.
Robust Cash Position
Cash on hand $34.1M, zero debt and positive operating cash flow of $2.4M, supporting continued investment and optionality (share buyback remains open).
AU:CGS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AU:CGS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 18, 2026 | AU$2.18 | AU$2.37 | +8.72% |
Aug 21, 2025 | AU$1.72 | AU$1.80 | +4.59% |
Feb 19, 2025 | AU$1.23 | AU$1.31 | +6.85% |
Aug 21, 2024 | AU$1.13 | AU$1.02 | -9.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cogstate Ltd (AU:CGS) report earnings?
Cogstate Ltd (AU:CGS) is schdueled to report earning on Aug 18, 2026, Before Open (Confirmed).
What is Cogstate Ltd (AU:CGS) earnings time?
Cogstate Ltd (AU:CGS) earnings time is at Aug 18, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Cogstate Ltd stock?
The P/E ratio of Cogstate Ltd is N/A.
What is AU:CGS EPS forecast?
AU:CGS EPS forecast for the fiscal quarter 2026 (Q4) is 0.05.